CorMedix Inc.

DB:19KA Stock Report

Market Cap: €481.6m

CorMedix Management

Management criteria checks 2/4

CorMedix's CEO is Joe Todisco, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $2.46M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth €1.46M. The average tenure of the management team and the board of directors is 2.7 years and 2.8 years respectively.

Key information

Joe Todisco

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage25.1%
CEO tenure2.7yrs
CEO ownership0.3%
Management average tenure2.7yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Joe Todisco's remuneration changed compared to CorMedix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensation vs Market: Joe's total compensation ($USD2.46M) is above average for companies of similar size in the German market ($USD973.98K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

CEO

Joe Todisco (48 yo)

2.7yrs

Tenure

US$2,459,432

Compensation

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022. He has served as Director of CorMedix Inc. since March 18, 2022 and served as its Independ...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Director2.7yrsUS$2.46m0.30%
€ 1.5m
Matthew David
Executive VP & CFO4.7yrsUS$1.03m0.017%
€ 82.8k
Erin Mistry
Executive VP & Chief Commercial Officer4.8yrsUS$1.26m0.024%
€ 115.2k
Elizabeth Masson-Hurlburt
Executive VP and Chief Clinical Strategy & Operations Officerless than a yearUS$844.81k0.013%
€ 62.7k
Kaufman Zelnick
Executive VP1.1yrsno datano data
Donna Ucci
Senior VP & Head of Global Quality2.7yrsno datano data
Tushar Mukherjee
Senior VP & Head of Technical Operations2yrsno datano data

2.7yrs

Average Tenure

47yo

Average Age

Experienced Management: 19KA's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Todisco
CEO & Director2.8yrsUS$2.46m0.30%
€ 1.5m
Myron Kaplan
Independent Chairman of the Board8.8yrsUS$191.96k0.30%
€ 1.4m
Alan Dunton
Independent Director5.8yrsUS$141.42k0.025%
€ 121.0k
Janet Dillione
Independent Director9.4yrsUS$147.42k0.088%
€ 424.5k
Steven Lefkowitz
Independent Director7.6yrsUS$162.42k0.13%
€ 615.2k
Gregory Duncan
Independent Director4.2yrsUS$141.42k0%
€ 0
Bruce Polsky
Member of Scientific Advisor Boardno datano datano data
Saravanan Balamuthusamy
Member of Scientific Advisory Board2.8yrsno datano data
Sara Bonnes
Member of Scientific Advisory Board2.8yrsno datano data
Aru Narendran
Member of Scientific Advisory Board2.8yrsno datano data
Hannah Newman
Member of Scientific Advisory Board2.8yrsno datano data
Jonathan Waitman
Member of Scientific Advisory Board2.8yrsno datano data

2.8yrs

Average Tenure

68yo

Average Age

Experienced Board: 19KA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 11:58
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CorMedix Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Edward WhiteFBR Capital Markets & Co.
Morris AjzenmanGriffin Securities